During the development of a new therapeutic, few pharmacodyamic outcomes currently receive as much scrutiny as the effect of a potential medication on the electrocardiographic QT interval. The recent withdrawal from marketing of several drugs due to potential drug-related cardiac arrhythmias have greatly increased concern about drug-related changes on the QT interval. In order to reduce the incidence of these idiosyncratic episodes, regulatory agencies have suggested that sponsors use more rigorous methodology during the safety evaluation of new pharmaceuticals. Along with enhanced electrocardiographic assessments during clinical trials, advanced preclinical examinations of effect on QT interval and ventricular repolarization have become de rigueur. In this arena, the beagle dog is the preclinical species often associated with the most reliable predictivity for human safety assessment. To this end, canine models of cardiovascular safety assessment are discussed along with the relevance of these assays to human electrocardiography.
INTRODUCTION
In 1996, a group of experts convened under the auspices of the Committee for Proprietary Medicinal Products (CPMP), an arm of the European Agency for the Evaluation of Medicinal Products (EMEA), to examine preclinical and clinical testing of new pharmaceuticals for the potential to prolong the electrocardiographic QT interval. The outcome of these meetings were summarized in a 1997 Points to Consider document entitled; "The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products" (13) . Since 1997, worldwide regulatory agencies have strengthened their positions on studying the interaction of compounds with the ventricular repolarization process. The International Conference on Harmonization has recently drafted guidelines (ICH S7B, working title: "Guideline on Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization [QT Interval Prolongation] by Human Pharmaceuticals," that define the required preclinical studies in this area (33) .
It is clear that agencies involved with marketing approval of new pharmaceuticals will continue to be vigilant for potential effects on QT interval. The basis of concern surrounding drug-induced QT interval prolongation arises from recent experience suggesting a link between this characteristic and cardiac arrhythmias (21, 38, 45, 48, 52) including torsade de pointe that may progress to a fatal ventricular fibrillation. A cursory examination of the compounds associated with these properties reveal a highly diverse chemical structure set and seemingly nonrelated pharmacological targets. These therapeutics include several antibiotics (24, 35) (some macrolides; erythromycin and other protein synthesis inhibitors, fluoroquinolones, DNA synthesis inhibitors; grepafloxacin), antifungals (3, 57) (fluconazole, ketoconazole), an agent for gastrointestinal prokinesis (17, 37, 50, 66) (cisapride), histamine H1 receptor antagonists (5, 9, 14, 25, 36, 38, 39, 72, 75) (terfenadine, diphenhydramine, astemizole, phenothiazine derivatives), as well as antipsychotic agents (44) (phenothiazine derivatives, haloperidol, sertindole, risperidone). These compounds, although certainly not meant to be an exhaustive list, have been shown to cause serious and potentially fatal cardiac arrhythmias. Some of these agents have been removed from the market, yet others continue to be available via prescription or through over-the-counter avenues (51) . Although the aforementioned list contains few examples of the latter (eg, diphenhydramine), it is clear that associations between QT prolongation, marketed drugs, and cardiac arrhythmias (at the extreme) continue to accrue.
Additional risk factors that are believed to contribute to this arrhythmogenesis include perturbations in serum potassium and magnesium (43) , concomitant cardiovascular pathology (34, 67) , congenital long QT syndrome (1, 53, 60, 65, 70) , and simultaneous administration of pharmaceuticals known to prolong the QT interval (47) or inhibit the metabolic disposition of the aforementioned compounds (42) . Information continues to accrue that broadens the complexity of the situation. For instance, since the recognition of the aforementioned drug-induced proarrhythmias, a heightened awareness exists around a pharmaceutical's ability to prolong the QT interval in the absence of demonstrated cardiac rhythm disturbances. Many successful medicines have verbiage in the product insert describing a potential for QT interval prolongation.
Recognizing the volatility of these developments, the pharmaceutical industry now examines compounds to alleviate the risk associated with postapproval marketing of medicines potentially possessing these deleterious side effects. These examinations include additional preclinical studies, usually comprising of in vitro ion channel studies, in vitro action potential duration assays, and in vivo animal studies. In addition, robust clinical examination of drug-induced effects on ECG may be warranted. To interpret the regulatory guidance and understand the basis for this new "integrative risk assessment," the reader should be aware of terminology 12 GRALINSKI TOXICOLOGIC PATHOLOGY and concepts mentioned in this field. This review will discuss the anatomy and physiology surrounding the generation of the electrocardiographic QT interval, and the consequences of its alteration. The critical role of the dog as a preclinical model of cardiovascular electrophysiology assessment is discussed in the context of relevant cardiac safety models.
MYOCARDIAL ELECTROPHYSIOLOGY Ionic Channels: Associated Currents and Assays: The generation of myocardial action potentials occurs when the cellular membrane depolarizes beyond a threshold voltage. This depolarization is mediated via transient changes in ionic (sodium, potassium, and calcium) permeability (69) . Ionic movement across electrical and concentration gradients alternately depolarizes and repolarizes the myocellular membrane resulting in the action potential ( Figure 1 ). A multitude of ionic channels modulate and contribute to the action potential, and certain specific examples are discussed in this review. Studies of these channels have led to an understanding of how different ion currents contribute to membrane depolarization and repolarization. As alluded to earlier, regulatory authorities are drafting guidelines currently stating that in vitro electrophysiological studies should be performed as part of the schemata to determine any potential effects on cardiovascular function (33). Although the guidelines are still under discussion, it is clear that assays examining the effect of a new chemical entity (NCE) on repolarizing ionic current and/or action potential duration ex vivo should be considered prior to first in human administration. As we shall discuss, they have also lead to an assessment of the various laboratory animals with regard to which species utilize similar ionic channels as humans. However, for an in-depth analysis the reader is referred to available publications detailing the field of cardiac electrophysiology at the molecular level (8, 61, 62) . Compounds that increase the QT interval tend to block highly specific ionic repolarizing currents. Elucidation of the antagonized ionic channel can lead to a molecular "causeand-effect" that may predict the possibility of QT interval prolongation, or explain the observance of this phenomena in vivo. Usually, but not exclusively (41) , this involves antagonism of the delayed rectifying potassium currents (54, 73) . No discussion of ventricular repolarization methodology is complete without mentioning the putative role of the ionic channel assay. This assay is most often performed with human cells (ie, embryonic kidney) transfected with the gene expressing an ionic channel of interest. For example, the cloned human ether-a-go-go related gene (hERG) may be transfected into a stable cell line. hERG contains the human I kr repolarizing channel as its expression product (29, 58, 59) . Using patch-clamp techniques, ionic current arising exclusively from the tranfected channel can be measured in the presence and absence of test article. With this paradigm, it is fairly straightforward to demonstrate an inhibition, or lack thereof, of repolarizing current by the compound of interest. When using these experimental models, one should examine the compound of interest against recognized positive controls with respect to ionic channel blockade. To maximize the efficiency of these assays, many organizations have implemented cloned channel assays in a high throughput screening fashion. Clearly, if these assays prove to be reliable with the identification of compounds that could prolong ventricular refractoriness, early introduction of these tests can refine the drug discovery process and help to procure a safer compound to the clinical setting in a more rapid manner.
The Myocardial Action Potential Duration Assay: There are 5 distinct phases of the myocardial action potential. These individual phases refer to the predominant ionic current during a particular span in time ( Figure 1 ). The upstroke of the action potential, phase 0, is associated with the rapid inward movement of sodium ions into the myocytes of the normal atria, Purkinje, and ventricular cells resulting in depolarization. This very rapid and intense influx of sodium (termed I Na ) is quickly followed by inactivation of the sodium channels. Interestingly, many calcium channels become activated and inactivated in a similar manner to the sodium channels. However, the transitions occur more slowly at more positive transmembrane potentials. After phase 0, a transient outward repolarizing potassium current (I to ) is associated with the phase 1 notch in many species, and signals the beginning of cellular repolarization. A plateau occurs during phase 2, reflecting an ionic balance struck between an inward depolarizing calcium current (I ca ++ ) and outward repolarizing potassium currents, the delayed rectifiers I Kr and I Ks . Because the calcium currents begin to inactivate and decrease in frequency over time, the delayed rectifier currents are responsible for the predominating ionic movement. This portion, phase 3, is the repolarization segment of the myocardial action potential. The phenomenon of spontaneous depolarization, such as that occurring in phase 4, is not well understood. The Na + /K + pump and Na + /Ca ++ exchanger may play roles during phase 4, the period that brings the transmembrane potential towards threshold voltage. This resetting of the transmembrane potential allows a new action potential to be generated. The summation of these currents across the myocardium are responsible for initiating and controlling the cardiac cycle of contraction and relaxation.
Role of Dog-In Vitro:
Along with the large historical canine database that facilitates interpretation of results, the molecular milieu of canine ventricular tissue resembles that of the human heart. As previously mentioned, blockade of inward rectifying channels (eg, I Kr ) is the ionic mechanism most associated with acquired long QT syndrome. Wymore and colleagues (74) examined the distribution of mRNA for the I Kr -like potassium channel in guinea pig, rabbit, human, dog, and rat cardiac tissue. The study revealed that erg message is found in the hearts of all 5 species and that it is expressed uniformly throughout the heart. Examination of the other ionic channels involved with repolarization uncover the favorable correlation between human and canine ventricle when compared to other species with respect to repolarization mechanisms. In the rat, it had long been believed that this species did not utilize I Kr to repolarize the ventricle. There was a variety of "evidence" supporting this school of thought. Primarily, the rat has a very short action potential plateau followed by a steep decline toward baseline suggesting either a minimal role for I Kr and I Ks or a different pattern of ionic movement (27) . We now know that in contrast to I Kr , the transient outward current (I to ) plays a dominant role with respect to repolarizing the rat ventricular conduction system (18) . This explains the characteristic action potential morphology observed in this species. In addition to the molecular differences, the rat (as well as other rodent species) possesses a high heart rate making actual measurement of the electrophysiological intervals with acceptable precision exceedingly difficult.
The guinea pig has also been used extensively for repolarization studies. This species has been described as having fairly good correlation to human AP prolongation using known agents that lengthen QT interval (22) . On a molecular basis, the guinea pig does not appear to express Ito current (18) , and the predominant portion of the repolarizing current is due to the slow activating delayed recitifer I Ks (30) . Although this channel plays a role in the dog, human, and rabbit, its predominance in the guinea pig distances it from the human with regard to repolarization mechanism of action.
The rabbit, pig, and dog all possess channel distribution and activity resembling the human cardiac channel conduction system. With respect to action potential durations measured ex vivo, forthcoming guidelines will most likely avoid recommending a particular species as a source of tissue. Concentration selection is paramount because it is well established that certain compounds shorten the action potential duration at some concentrations while actually increasing it at other levels (4, 12) . Along with a choice of species, the type of tissue chosen from the ventricle for APD assays varies. The overwhelming majority of researchers conducting this assay use the Purkinje fiber for measuring APD (28) . The other cardiac tissue with any reasonable usage frequency is the papillary muscle. Action potentials recorded from papillary muscle should be interpreted with caution however, because some compounds associated with small changes in this preparation have been shown to confer greater alterations in action potential duration assays with canine Purkinje fibers (55) .
An appendix of the benefits and caveats associated with particular species and assays is under consideration. However, a powerful combination of the in vitro and in vivo historical database and toxicological data from the dog is a compelling argument for the use of the dog Purkinje fiber as the preclinical model of choice for routine measurement of test article effects on action potential duration. Hammond et al reported the survey results of institutions conducting this assay, and concluded that indeed the predominant species of choice is the dog (28) . From a practical perspective a large database is being generated through the use of this species. A cursory literature check confirms the increasing amount of reference material available from dog tissue procured for APD studies. In addition, the use of dogs as the predominant nonrodent toxicology species is complementary with respect to comparing APD data obtained ex vivo with electrocardiographs obtained in vivo. Indeed, Gintant and colleagues have recently demonstrated a high correlation between action potential prolongation in dog purkinje fibers and increasing QT interval in humans with positive control pharmaceuticals (23) . The importance of further examination into the correlation of in vitro assays with human data cannot be underestimated.
QT INTERVAL AND IN VIVO METHODOLOGY
For this discussion, the correlation between the myocardial action potential and the surface electrocardiogram will be confined to the association between action potential duration and the QT interval. The QT interval represents the time frame of ventricular depolarization and repolarization. Because the depolarization period is extremely short in comparison to repolarization, it is assumed that changes in QT interval are manifest upon interference with the repolarization process. In the case of sodium channel blockade, QRS complex duration is characteristically increased. With such a scenario, one must look at the J-T interval (QT interval minus QRS duration) as a temporal measure of the repolarization process. In most cases however, the QT interval is an accurate representation of repolarization. A few caveats exist when examining the effects of pharmaceutical compounds on the QT interval. Metabolic disposition of the test article, statistical power of the study, and quality of electrocardiographic data and analysis are potential pitfalls. Foremost among all these is the rate-dependent nature of the QT interval. In most species examined, it is well-established that the duration of the QT interval is inversely related to the heart rate (HR) of the subject under examination (7, 40) . Thus, any changes in the raw QT interval must be carefully interpreted and reported with caution.
Since the QT interval has a rate-dependent nature, investigators have devised various mathematical formulae to adjust this variable for values obtained at different heart rates resulting in a "corrected" QT interval (the QTc). Bazett stated that the QT interval should be divided by the square root of its associated R-R interval (RR interval = (1/(HR/60)); thus, QTcB = QT/ÖRR) (7) . Fredericia deviated from Bazett's formula with a cube root basis for correction (QTcF = QT/3ÖRR) (20) . These clinically used indices of cardiac repolarization are not without drawbacks, especially when used with other species. For example, Bazett's correction formula is inappropriate and inaccurate for high or low heart rates, 14 GRALINSKI TOXICOLOGIC PATHOLOGY resulting in an over-and underestimation of the true length of the repolarization process in certain species, most notably the dog (16) . In recent years, investigators have developed other formulae to adjust the QT interval, including those involving linear regression and analysis of covariance equations (2, 6, 15, 56, 63, 64) . Recent reports propose that QT "correction" itself may be inappropriate and the investigators involved with these studies suggest alternate solutions (19) .
In the current environment, it is probably prudent to report the corrected QT interval as a well-characterized point of reference with recognition that in a few years the QTc may be of little scientific value as our understanding of this relationship develops.
As mentioned, thorough examinations of a compound's general pharmacodynamic properties and toxicological activities are included in the safety assessment of any new chemical entity. The ICH recommends that cardiovascular safety pharmacology studies and repeat dose nonrodent toxicity studies be performed, most typically in the dog or primate (31, 32) . These studies should be robust and should contain acquisition of hemodynamics and electrocardiograms over a range of escalating doses including those producing moderate toxicity in studies of similar duration (32).
Role of Dog-In Vivo:
Recording the surface electrocardiogram has been the basic gold standard for determining effects of pharmaceutical compounds on cardiac electrophysiology. In most cases, electrocardiograms are obtained as a component of the nonclinical evaluation studies, including safety pharmacology and toxicology assessments. The majority of evidence confirms the dog's role as the most predictive preclinical species with regard to human electrocardiography (16) . Detweiler provides a compelling discussion concerning the use of different species in electrocardiographic assessments. As previously mentioned, the rat should be considered anomalous with respect to the human ECG due to the overwhelming role of I to in the repolarization process. Although the use of nonhuman primates is increasing due to a variety of development factors (limited compound requirements, canine toxicity, biotechnology products), Detweiler describes the nonhuman primate (namely, cynomolgous monkey) as the most misleading species. The reasons for this are varied, but primarily focus on the inherent characteristics of the species in addition to the technical challenges presented with the model. Clearly, cost and ethical concerns also play a key role in the decision process. Most investigators continue to rely on the dog, although a few also examine effects on ECG in other species. Recognizing the expert opinion on the utility of the dog as a preclinical predictor of human electrocardiography, the value of these additional examinations remains dubious for most traditional NCEs.
For standard toxicology studies, electrocardiograms are usually recorded in either a single Lead II or multilead configuration. Animals should be conscious, although some investigators also rely on data from anesthetized subjects (49) . If anesthetized animals are used, consideration should be given to the ancillary effects of the anesthetic on cardiovascular parameters, especially the QT interval. Most anesthetic agents affect hemodynamics and/or electrophysiology to the extent that their use should be restricted to special circumstances (26) .
For a detailed examination of a compound's potential for QT interval prolongation, the dog that has been instrumented with telemetry technology is currently considered by many as the gold standard model. Conscious, restrained animals of all species have artificially raised heart rates and sympathetic drive that can easily confound interpretation of electrocardiographic effect. For example, in the beagle dog we have recorded heart rates of approximately 50-100 beats per minute (bpm) in the unrestrained telemeterized subject, while those manually restrained present with rates of 90-130 bpm. Numerous correction formulae have been developed to adjust for the inverse relationship between heart rate and QT interval, although the shortcomings of these mathematical interpolations are many. Many methods of correction, and indeed noncorrection, have been proposed (2, 6, 15, 19, 56, 63, 64) . Although the use of conscious sling-trained dogs can reduce the variability observed in the restrained animal, it is still considered preferable to utilize telemetry implants that derive cardiovascular parameters from the conscious, freeroaming animal. In certain cases, Holter technology can be used with the dog in lieu of implanted telemetry. Utilizing this route of examination, animals are not necessarily subjected to surgery and recovery periods (and their potential sequella) as is the case with most telemetry collection systems. With either route, the experimental subject is allowed to remain in its home cage and undisturbed while these measurements are collected and stored by data acquisition systems. In theory, this allows for the maximum amount of relevant information to be captured with a minimum of potentially confounding interactions.
Indeed, a recent survey on the correlation between nonclinical safety assessment paradigms and the toxicity of human pharmaceuticals revealed that the dog's prediction of human cardiovascular toxicities was among the highest of animal species studies (46) . Roughly 85% of human cardiovascular toxicities were predicted by studying the dog, a testimony to its historical usage and physiological similarity.
If electrocardiographic examinations result in changes with QT interval (or other ECG intervals), it is possible to perform detailed in vivo electrophysiological studies. These experimental studies include monophasic action potential duration measurements via the use of special electrodes, and proarrhythmia models. These time-consuming and technically challenging experiments are usually best performed by individuals possessing extensive experience with in vivo preparations and the subtleties associated with these models. Examination of the monophasic action potential in vivo is most often performed using the anesthetized dog. Briefly, MAP electrodes can be placed on the epicardial and endocardial surface of the myocardium and action potentials can be recorded prior to and following test article administration. Thus, apparent changes in the QT interval can be examined at the source of this parameter, the ventricular monophasic action potential. An anesthetized canine model utilizing animals with chronic idioventricular bradycardia after complete AV block is also available to examine proarrhythmic potential (68) . Programmed electrical stimulation can induce early afterdepolarizations (EADs) and polymorphic VT in the presence of repolarization-altering agents with this preparation. Major caveats with proarrhythmia assays include their technical complexity (11, 71) and minimal evidence suggesting predictivity for humans, although the latter characteristic is primarily due to the very low frequency of performance. A lack of qualified and highly trained in vivo physiologists and pharmacologists significantly contributes to this gap in the database, but that discussion is beyond the scope of this article.
CONCLUSIONS
Although the participants involved with setting policy on examining the potential for QT prolongation continue to refine their opinions, pharmaceutical sponsors are left to develop rationale for addressing this concern. Some organizations are focusing early endeavors on high-throughput screens to eliminate compounds with ionic channel blockade from advancement. Others are using a more integrative approach combining knowledge gained from in vitro assays with data obtained from aforementioned in vivo techniques. Although it is clear that the dog will continue serving a critical role in cardiovascular safety assessment, it is important to emphasize that no one model will give a definitive result and thus a multiplicity of studies must be undertaken to understand the relevance and predictability for assessing human safety.
As sponsors are struggling to bring new pharmaceuticals to market using abbreviated timelines, financial restrictions, and novel or first-in-class mechanisms of pharmacologic efficacy, the industry must continue to choose the most relevant preclinical models predicting potential human toxicities. It is clearly apropos that validation work in this area continue via professional avenues and collaborations. These experiments will greatly strengthen our ability to refine the drug development scheme, reduce the resources spent on futile molecules, and of greatest importance provide safe and efficacious treatments for the patient population.
